Journal profile · PHARMACOLOGY & PHARMACY
Pharmaceutical Patent Analyst
ISSN 2046-8954 · eISSN 2046-8962 · Future Science
Pharmaceutical Patent Analyst: CAS Zone 4 · Medicine (2025 upgraded edition); subscription journal; median 154 days to acceptance (13 articles, last 24 months); 0 articles in 2025; indexed in Scopus; flagged on an early-warning list or for an indexing change: check before submitting.
Scope
Aims, scope and focus
Pharmaceutical Patent Analyst is published by Future Science and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Intellectual Property and Patents, Pharmaceutical Economics and Policy and Intellectual Property Law, together about 73.5% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Research area (LetPub): PHARMACOLOGY & PHARMACY
Main research topics OpenAlex counts of recent articles; shares are approximate
- Intellectual Property and PatentsBusiness, Management and Accounting30.1%
- Pharmaceutical Economics and PolicyEconomics, Econometrics and Finance24.4%
- Intellectual Property LawSocial Sciences19.1%
- Science, Research, and MedicineMedicine4.1%
- Nanoparticle-Based Drug DeliveryMaterials Science1.9%
- Advanced Drug Delivery SystemsPharmacology, Toxicology and Pharmaceutics1.9%
- Law, AI, and Intellectual PropertyComputer Science1.9%
- Biosimilars and Bioanalytical MethodsImmunology and Microbiology1.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
CiteScore quartiles (Scopus, June 2026 release)
| Subject | Quartile | Rank | Percentile |
|---|---|---|---|
| Pharmaceutical Science | Q2 | 91/191 | 52nd |
| Drug Discovery | Q3 | 109/161 | 32nd |
Scopus ranks journals by CiteScore within each subject: the 75th percentile and above is Q1, then a quartile every 25 points. A different system from the CAS zones.LetPub
Database indexing
ScopusLetPub
Early warning / risk: Marked as ceased in ESCI on 16 February 2026. CAS Early Warning Journal List: not listed in any of 6 editions.LetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 3.2LetPub ·
- SJR 2026-06
- 0.26LetPub ·
- SNIP 2026-06
- 0.22LetPub ·
- h-index
- 26OpenAlex ·
- i10-index
- 97OpenAlex ·
- 2-year mean citedness
- 2.33OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Volume
- Articles per year
- 12LetPub ·
Articles by year OpenAlex count · 547 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 0 | 0 | 177 |
| 2025 | 0 | 0 | 317 |
| 2024 | 24 | 24 | 318 |
| 2023 | 28 | 3 | 327 |
| 2022 | 30 | 2 | 342 |
| 2021 | 25 | 2 | 361 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
154 daysMedian, submission to acceptance · P25–P75 125 days – 195 days
- Acceptance to online
- median 20 days (13 articles)
- Submission to online
- median 174 days
- Sample
- 13 articles with submission and acceptance dates (14 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
No source has fee information yet; check the journal's website.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Future Science
- ISSN
- 2046-8954
- Electronic ISSN
- 2046-8962
- Official links
- Journal homepage ↗OpenAlex
FAQ
Frequently asked questions about Pharmaceutical Patent Analyst
What CAS zone is Pharmaceutical Patent Analyst in?
In the 2025 upgraded edition of the CAS Journal Ranking, Pharmaceutical Patent Analyst is in Zone 4 of Medicine, and in Zone 4 of the minor category Pharmacology & Pharmacy. Zones from different editions, and from major and minor categories, are not interchangeable.
How long does peer review take at Pharmaceutical Patent Analyst?
Based on the dates recorded on 13 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 154 days (interquartile range 125–195 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Pharmaceutical Patent Analyst?
According to LetPub and DOAJ records, Pharmaceutical Patent Analyst is indexed in Scopus.
Is Pharmaceutical Patent Analyst open access, and what is the APC?
Pharmaceutical Patent Analyst is a subscription journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .